STOCKHOLM, March 22, 2021 /PRNewswire/ -- Oncopeptides AB
(publ) (Nasdaq Stockholm: ONCO), a global biotech company focused
on the development of therapies for difficult-to-treat
hematological diseases, today announces that PEPAXTO®
(melphalan flufenamide) has been included in the new Multiple
Myeloma Clinical Practice Guidelines of the National Comprehensive
Cancer Network® (NCCN) in Oncology. PEPAXTO, in
combination with dexamethasone, was granted accelerated approval by
the FDA on February 26, 2021, for the
treatment of adult patients with relapsed or refractory multiple
myeloma who have received at least four prior lines of therapy and
whose disease is refractory to at least one proteasome inhibitor,
one immunomodulatory agent, and one CD38-directed monoclonal
antibody.
"The NCCN Guidelines are a trusted resource for clinicians
in the management of oncology patients," says Marty J Duvall, Chief
Executive Officer at Oncopeptides AB. "We are grateful that
melphalan flufenamide is included in these guidelines and believe
that they will facilitate the management of previously treated
multiple myeloma patients, who need additional treatment
options".
NCCN is an alliance of 30 cancer centers in the United States. Over the past 25 years,
NCCN has developed an integrated suite of tools to improve the
quality of cancer care. The NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines®) document evidence-based,
consensus-driven management to ensure that all patients receive
preventive, diagnostic, treatment, and supportive services that are
most likely to lead to optimal outcomes. To learn more about the
NCCN Guidelines® and Clinical Resources you may
visit www.nccn.org.
For more information, please contact:
Rolf Gulliksen, Global Head of
Corporate Communications, Oncopeptides AB (publ)
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28
Linda Holmström, Director of Investor Relations, Oncopeptides AB
(publ)
E-mail: linda.holmstrom@oncopeptides.com
Cell phone: +46 70 873 40 95
About melphalan flufenamide
Melphalan flufenamide, also known as melflufen, is the first
anticancer peptide-drug conjugate for patients with relapsed or
refractory multiple myeloma. Melphalan flufenamide uses innovative
technology that links a peptide carrier to a cytotoxic agent,
resulting in a lipophilic compound. Due to its high lipophilicity,
melphalan flufenamide is distributed into cells. Melphalan
flufenamide is designed to leverage aminopeptidases, which are
overexpressed in multiple myeloma cells and cause the release of
cytotoxic agents. Melphalan flufenamide is administered once
monthly, by a thirty-minute infusion.
In the US, PEPAXTO® (melphalan flufenamide) is
indicated in combination with dexamethasone for the treatment of
adult patients with triple class refractory multiple myeloma, who
have received at least four prior lines of therapy and whose
disease is refractory to at least one proteasome inhibitor, one
immunomodulatory agent, and one CD38-monoclonal directed antibody.
PEPAXTO® is a registered trademark in the U.S.
About Oncopeptides
Oncopeptides is a global biotech company focused on the
development of targeted therapies for difficult-to-treat
hematological diseases. The U.S. Food and Drug Administration has
recently granted PEPAXTO (melphalan flufenamide, also known as
melflufen), accelerated approval in relapsed or refractory multiple
myeloma. Melphalan flufenamide is the first drug originated from
the Company's proprietary PDC-platform and is evaluated in a
comprehensive clinical study program, including the ongoing phase 3
OCEAN study. Melphalan flufenamide is the first anticancer
peptide-drug conjugate for patients with relapsed or refractory
multiple myeloma. The drug uses innovative technology that links a
peptide carrier to a cytotoxic agent, resulting in a lipophilic
compound. Due to its high lipophilicity, it is distributed into the
cells. Melphalan flufenamide is designed to leverage
aminopeptidases, enzymes which are overexpressed in myeloma cells
and cause the release of the cytotoxic agents in the cells.
Oncopeptides' global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is
situated in Boston, Mass. The
company is listed in the Mid Cap segment on Nasdaq Stockholm with
the ticker ONCO. More information is available
on www.oncopeptides.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/oncopeptides-ab/r/oncopeptides-announces-that-pepaxto--is-included-in-new-multiple-myeloma-guidelines-of-national-comp,c3311547
The following files are available for download:
https://mb.cision.com/Main/15404/3311547/1390624.pdf
|
Press release -
Oncopeptides announces that PEPAXTO® is included in new Multiple
Myeloma guidelines of National Comprehensive Cancer
Network®
|
View original
content:http://www.prnewswire.com/news-releases/oncopeptides-announces-that-pepaxto-is-included-in-new-multiple-myeloma-guidelines-of-national-comprehensive-cancer-network-301252793.html
SOURCE Oncopeptides AB